Metrics as of 10/17/2026, 12:22 AM (Berlin time), refresh in progress.
Gossamer Bio Stock
Gossamer Bio, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Faheem Hasnain
- Employees
- 162
- Market cap
- $54 M
- IPO
- 08/02/2019
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or…
Gossamer Bio stock: price history
1D
-1.3%
1W
-5.8%
1M
-20.0%
6M
-75.4%
YTD
-96.5%
1Y
-95.3%
2Y
-88.7%
5Y
-99.2%
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~5% weaker price swings than usual
Ask the agents about Gossamer Bio
Analyst assessment of Gossamer Bio
PRICE TARGET LOW
US$0.30
CONSENSUS
US$3.47
MEDIAN
US$3.00
PRICE TARGET HIGH
US$9.00
0
STRONG BUY
11
BUY
5
HOLD
2
SELL
0
STRONG SELL
18
TOTAL · Buy
As of: 15/10/2026
Gossamer Bio stock metrics
P/E
-0.19
P/B
-0.26
EV/EBITDA
-0.25
RETURN ON EQUITY
-18.0%
NET MARGIN
182.9%
DEBT/EQUITY
-0.42
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
26.3%
FLOAT SHARES
1,609,547
AVG. DAILY VOLUME (30D)
296,852
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Gossamer Bio stock
What does Gossamer Bio do?
Gossamer Bio, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Faheem Hasnain, the company employs around 162 people.
The IPO was on 08/02/2019; the stock trades on NASDAQ under the ticker GOSS.
What do analysts say about Gossamer Bio stock?
18 analysts rate the stock, the consensus is Buy (as of 15/10/2026).
The average price target is US$3.47, ranging from US$0.30 to US$9.00, with a median of US$3.00.
This is an external assessment, not a statement by Market Jury.
When does Gossamer Bio report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly -5% stronger than usual.
Does Gossamer Bio pay a dividend?
No, Gossamer Bio currently does not pay a dividend.
Which stocks are comparable to Gossamer Bio?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Gossamer Bio stock analyzed?
Clicking "Analyze stock" lets five strategies assess Gossamer Bio against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.